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In sub-Saharan Africa, HIV-1 infection frequently occurs in the context of other coinfecting pathogens, most
importantly, Mycobacterium tuberculosis and malaria parasites. The consequences are often devastating, re-
sulting in enhanced morbidity and mortality. Due to the large number of confounding factors influencing
pathogenesis in coinfected people, we sought to develop a nonhuman primate model of simian immunodefi-
ciency virus (SIV)-malaria coinfection. In sub-Saharan Africa, Plasmodium falciparum is the most common
malaria parasite and is responsible for most malaria-induced deaths. The simian malaria parasite Plasmodium
fragile can induce clinical symptoms, including cerebral malaria in rhesus macaques, that resemble those of P.
falciparum infection in humans. Thus, based on the well-characterized rhesus macaque model of SIV infection,
this study reports the development of a novel rhesus macaque SIV-P. fragile coinfection model to study human
HIV-P. falciparum coinfection. Using this model, we show that coinfection is associated with an increased,
although transient, risk of both HIV and malaria transmission. Specifically, SIV-P. fragile coinfected macaques
experienced an increase in SIV viremia that was temporarily associated with an increase in potential SIV target
cells and systemic immune activation during acute parasitemia. Conversely, primary parasitemia in SIV-P.
fragile coinfected animals resulted in higher gametocytemia that subsequently translated into higher oocyst
development in mosquitoes. To our knowledge, this is the first animal model able to recapitulate the increased
transmission risk of both HIV and malaria in coinfected humans. Therefore, this model could serve as an
essential tool to elucidate distinct immunological, virological, and/or parasitological parameters underlying
disease exacerbation in HIV-malaria coinfected people.
HIV and malaria represent two of the most serious health
problems. Worldwide, Plasmodium species are responsible for
300 to 600 million clinical malaria episodes and 1.2 million
deaths annually (23). Most of the malaria-associated deaths
can be attributed to infection with Plasmodium falciparum, the
parasite most common in sub-Saharan Africa. Sub-Saharan
Africa is also the epicenter of the HIV pandemic, with more
than 20 million HIV-1-infected people (44). The geographical
overlap urges a combined effort in combating both diseases.
Importantly, there is a need to understand how both pathogens
interact with each other and alter host immune responses in
coinfected individuals.
The clinical and epidemiological importance of coinfection
with HIV and P. falciparum has been disputed. Initial studies
did not find increases in morbidity and HIV transmission due
to coinfection and concluded that coinfection was only a geo-
graphical coincidence (8). More recent data, however, suggest
that HIV-1-infected people are at greater risk for severe ma-
laria and, conversely, that malaria episodes in HIV-1-infected
people result in increased viremia and morbidity (5, 12, 20, 22,
24, 27, 28, 47, 50). Mathematical models estimate that en-
hanced malaria incidence due to HIV-1 infection translates
into an additional 3 million malaria cases and 65,000 deaths
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due to HIV-1 annually (27). A similar modeling approach
predicted that coinfection in Kenya had resulted in an excess of
8,500 HIV-1 infections and 980,000 malaria infections since
1980 (3).
Multiple confounding factors will influence the outcome of
coinfection: age, time of coinfection (acute or chronic phase of
HIV infection), preexisting immunity to malaria (areas of sta-
ble versus unstable transmission), degree of HIV-1-induced
immunosuppression, and dysfunction of immune cells due to
malaria infection. A relevant animal model would facilitate
better definition of pathogen interactions and identification of
immune mechanisms leading to disease exacerbation in coin-
fected animals under controlled conditions. Recently, Koehler
et al. showed in a nonhuman primate model of simian immu-
nodeficiency virus (SIV) and Plasmodium cynomolgi infection
that coinfected animals experienced acceleration to simian
AIDS and impaired antimalarial immune responses (26). Clin-
ically, infection with P. cynomolgi closely reflects symptoms of
human Plasmodium vivax infection. Considering that the ma-
jority of HIV-1 and malaria infections occur in sub-Saharan
Africa, we sought to develop a rhesus macaque SIV-malaria
coinfection model that would more closely mimic human HIV-
1–P. falciparum coinfection. Among the primate malarias, four
species are recognized as “falciparum-like”: the type species P.
falciparum, Plasmodium coatneyi, Plasmodium fragile, and Plas-
modium reichenowi (11). While a gametocyte-producing strain
of P. falciparum was developed and was shown to be infective
for Aotus spp. (14, 37, 52), New World monkeys, which include
Aotus, are in general less susceptible than are Old World spe-
cies to SIV infection (25, 34). Similarly, P. reichenowi infects
only anthropoid apes (e.g., chimpanzees, gorillas). Among the
falciparum-like species, only P. coatneyi and P. fragile can infect
Macaca mulatta. Blood-induced infections with P. coatneyi in
M. mulatta, however, can result in rapid death in a large pro-
portion of infected animals (11). In contrast, P. fragile infection
is more readily controlled (11). Further, P. fragile can be con-
tinuously cultured in vitro (9) and, therefore, has been more
frequently used for drug and vaccine studies than has P. coat-
neyi (4, 15, 21, 43). Lastly, P. fragile is not infectious to humans
(49), which is an important consideration for biosafety man-
agement. Although P. fragile and P. falciparum are only dis-
tantly related and the course of P. fragile infection in its natural
simian host has not been extensively studied, we chose the
simian parasite P. fragile, because P. fragile can, similar to P.
falciparum in humans, induce a nonrelapsing disease and ce-
rebral malaria in rhesus macaques (21).
In the current study, we present a novel rhesus macaque
SIV-P. fragile coinfection model. Our data demonstrate a tran-
sient increase in SIV viremia during acute malaria infection
and increased gametocytemia in the blood of SIV-P. fragile-
coinfected animals that results in enhanced oocyst frequencies
in mosquitoes. These results support epidemiological data that
HIV-malaria coinfection in humans can result in an increased,
although transient, risk of transmission of both HIV-1 and
malaria (5, 24, 28, 46). Furthermore, we show that increased
viremia is associated with malaria-induced immune activation.
Thus, the rhesus macaque model of SIV-P. fragile coinfection
could serve as an important tool to better understand comor-
bidity and thereby lead the way to novel therapeutic interven-
tions.
MATERIALS AND METHODS
Animals and infections. Adult male rhesus macaques were obtained from and
housed in accordance with the regulations of the American Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) at the
California National Primate Research Center (CNPRC). Three groups of ani-
mals were included in the study. SIV infections (n  2) were established via
intravenous (i.v.) inoculation with 103 50% tissue culture infective doses
(TCID50s) of SIVmac239. Malaria infections (n  3) were performed via i.v.
inoculation with 1  106 to 2  106 P. fragile-infected rhesus macaque erythro-
cytes prepared according to Methods in Malaria Research (29). In order to
establish chronic malaria, animals were treated with 150 mg quinine sulfate
(Qualaquin; URL Pharma, Inc., Philadelphia, PA) via orogastric intubation for
2 consecutive days when parasitemia rose above 0.5%. SIV-P. fragile coinfected
animals (n  6) were inoculated with SIV 28 days prior to inoculation with P.
fragile and treated with 150 mg quinine sulfate for 2 or 4 consecutive days (see
Results). For clarity and comparative analysis, all time points are reported based
on the time of SIV infection. Thus, day 0 corresponds to the time of SIV
infection in SIV-only and SIV-P. fragile-coinfected animals. Day 28 corresponds
to the time of P. fragile infection in SIV-P. fragile-coinfected animals and to the
time of P. fragile infection in P. fragile-only infected animals. For clarity, days
postinoculations with P. fragile are also listed.
During the acute stage of malaria infection, blood was collected every other
day to monitor hematocrit, parasitemia, and infectivity to mosquitoes. Thereaf-
ter, blood samples were collected weekly for parasitologic, virologic, immuno-
logic, and infectivity analyses. At necropsy, lymphoid tissues, liver, and brain
were collected for histological analysis of parasite presence.
DNA and RNA isolation. DNA or RNA was extracted from 250 l whole
EDTA blood collected in 1:3 in TRIzol LS (Invitrogen, Carlsbad, CA) according
to the manufacturer’s protocol. DNA and RNA samples were stored at 20°C
and 80°C, respectively.
Viral load measurement. Plasma RNA samples were analyzed for viral RNA
by a quantitative reverse transcrition-PCR (qRT-PCR) assay as described else-
where (10). Results are reported as viral RNA copies per ml of plasma.
Parasitemia measurement. Parasitemia and gametocytemia were assessed by
thin smears of peripheral blood stained with Giemsa stain in a total of approx-
imately 200 fields. Parasitemia is reported as a percentage of infected erythro-
cytes (infected red blood cells [iRBC]), asexual plus sexual stages, compared to
the total erythrocyte number, while gametocytemia is the percentage of sexual
stage-infected erythrocytes compared to the total infected erythrocyte number.
Considering that P. falciparum can be sequestered and that low P. fragile
parasitemia might be difficult to detect in thin blood smears, a quantitative PCR
assay based on the sequence of the 18S ribosomal subunit (GenBank M61722) of
P. fragile was developed for parasite detection in tissues and to test blood samples
that were negative by microscopic blood smear analysis. The sequences of for-
ward and reverse primers and TaqMan probe were as follows: forward, 5-CA
GCTTTTGATGTTACGGGTATTG-3; reverse, 5-CCTCTCCGGAATCGAA
CTCTAA-3; probe, 5-CCTAACATGGCTATGACGGGTAACGGG-3. PCR
was performed using 100 ng DNA, 300 nM primers, and 200 nM probe in a total
volume of 25 l with the 7900 ABI default PCR amplification program. A
plasmid clone of P. fragile 18S DNA was used as a positive control, and no-
template negative controls were included in each reaction set. In addition,
template DNA quality was confirmed by amplification of rhesus macaque CCR5
for each sample. Data were quantified via comparison to a plasmid standard
curve and are reported as copies/g total DNA. The assay sensitivity limit was 10
copies/g DNA. Based on the original blood volume used for DNA isolation and
the number of erythrocytes per microliter of blood available through a differen-
tial blood count, parasitemia could then be reported as percent P. fragile-infected
erythrocytes.
PCR was also developed for the detection of the sexual stage of P. fragile. To
quantify gametocytes in the peripheral blood, we developed a qRT-PCR assay
based on the gametocyte-specific gene 230. Because the sequence of P. fragile 230
was unknown, we aligned the known sequences from P. vivax, P. falciparum,
Plasmodium knowlesi, Plasmodium chabaudi, and Plasmodium yoelii (PF-
230_XM_001349564, PV-230_XM_001612970, PB-230_XM_672775, PC-
230_XM_739974, and PY-230_XM_002257909) and developed primers in con-
served regions based on the P. vivax sequence (AGAAATTCCGAGTGTGGT
GAGC, nucleotides 3579 to 3591, and CTTTGTTGTAGCCCTCCCCTTT,
nucleotides 3703 to 3724). PCR was performed using 1 AmpliTaq mastermix
(Applied Biosystems), 1.25 U AmpliTaq polymerase, 0.5 M primers, 200 M
deoxynucleoside triphosphates, and 300 ng DNA in a total reaction volume of 50
l. We amplified DNA from P. fragile-infected rhesus macaque blood samples on
a Veriti thermal cycler (Applied Biosystems, CA) under the following conditions:
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denaturation at 94°C for 3 min, 40 cycles of amplification (94°C for 30 s, 56°C for
30 s, and 70°C for 30 s) and a terminal extension at 70°C for 10 min. Subse-
quently, we isolated the gene product by using the QIAquick gel extraction kit
(Qiagen, CA), cloned the fragment into a plasmid (TOPA TA cloning kit;
Invitrogen, CA), and sequenced the plasmid (Davis Sequencing, Davis, CA). P.
fragile-specific primers (forward, 39, CATAAATGGTATCCAATAGCTTT
GCA; reverse, 136, AGCAAAGATCTGTCGTTCAAATGT) and probe (86,
CGTCAACGTGTACTCCTTCTTCAAAAGTACACACA) were then devel-
oped.
RNA isolated from whole blood was reverse transcribed into cDNA as de-
scribed previously (1, 2), and real-time PCR was performed with 100 ng of cDNA
using the ABI default program. The plasmid clone of P. fragile 230 was used as
a positive control, and no-template negative controls were included in each
reaction. Data were quantified via comparison to a plasmid standard curve and
reported as copies/l blood. Note that samples that tested negative for gameto-
cytemia by blood smear analysis also did not result in detection by gametocyte-
specific genes by PCR, confirming the specificity of the observed sequences.
Mosquito husbandry and feeding. Laboratory-reared adult female Anopheles
freeborni were used for transmission studies as described previously (16). For
each assay, a carton of 100 female mosquitoes was provided access to 1 ml of
heparinized, freshly drawn, warm peripheral blood from a P. fragile-infected or
SIV-P. fragile-coinfected animal via an artificial feeding apparatus. Following
blood feeding, mosquitoes were provided with 10% sucrose-soaked cotton pads.
Non-blood-fed mosquitoes were removed from the cartons, and the remaining
mosquitoes were maintained at 28°C with 80% humidity for 10 to 12 days. After
this time, midguts were dissected from mosquitoes with mature eggs (indicative
of complete engorgement) and stained with 1% mercurochrome to count P.
fragile oocysts (19). Mosquito infectivity is reported as the percentage of mos-
quitoes with at least 1 oocyst relative to the total number of blood-fed mosqui-
toes.
Tissue H&E staining. For light microscopy, tissues were fixed in 10% buffered
neutral formalin for 24 h and then stored in 70% ethanol until paraffin embed-
ding. Tissues were sectioned at 4 m and stained with hematoxylin and eosin
(H&E).
Phenotypic characterization of lymphocyte populations. Multiparameter flow
cytometric analyses were performed to characterize lymphocyte populations in
whole peripheral blood. All antibodies were from BD Biosciences (San Jose,
CA). T cell activation and proliferation of CD4-positive T cells (CD3 clone
SP34-2 and CD4 clone L200) were defined by using antibodies to CCR5 (clone
3A9) and to Ki67 (clone B56), respectively. Samples were acquired on a FACS
ARIA apparatus (Beckton-Dickinson), and data were analyzed using FlowJo
software (TreeStar; Ashland, OR) as described previously (30, 48). Data are
reported as the frequency of CD3 CD4 lymphocytes that stained positive for
an individual marker.
Measurement of plasma NO and cytokine levels. Plasma nitric oxide (NO)
levels were measured using the QuantiChrom nitric oxide assay by BioAssay
Systems (Hayward, CA) according to the manufacturer’s protocol. Undiluted
plasma samples were assayed in duplicate, and average data are reported as M
NO in plasma. Levels of gamma interferon (IFN-) and interleukin-6 (IL-6) in
plasma were determined using the Th1/Th2 nonhuman primate bead array
(Beckton-Dickinson).
Statistical analysis. To assess differences in virologic outcomes between SIV-
only (n  7) and SIV-P. fragile-coinfected animals (n  5), we compared levels
of SIV replication from 4 weeks post-SIV infection (p.i.), the time of P. fragile
infection, until after resolution of primary parasitemia. Specifically, as primary
parasitemia generally became detectable between days 10 and 14 p.i. with P.
fragile, the slope of viral RNA between days 42 and 56 p.i. with SIV-SIV was
compared with the exact Wilcoxon rank-sum test. Estimates of slopes were
obtained from a linear model using all available plasma RNA values from days
42 to 56. Day 28 plasma RNA values were imputed for day 42 for 2 animals in
FIG. 1. P. fragile and SIV-P. fragile animal models. The data show the correlation between hematocrit (dotted line) and parasitemia, measured
as the percentage of infected RBC per total RBC by blood smear (solid red line) or as total copies of P. fragile DNA per total RBC by PCR analysis
(solid black line) in P. fragile-infected (A) and SIV-P. fragile-coinfected (B and C) animals. Asterisks indicate the time of quinine sulfate treatment.
A 2-day treatment effectively induced chronic parasitemia in P. fragile-only-infected (A), but not in SIV-P. fragile-coinfected (B) animals.
(C) Chronic parasitemia in SIV-P. fragile-coinfected animals was induced by a 4-day quinine sulfate treatment.
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the SIV-only group, due to missing values. Plasma viral RNA values from 5
historical age-matched SIV control animals were included due to the low number
(n  2) of concurrent SIV control animals. The historical SIV-positive animals
were also infected intravenously.
Differences in gametocytemia between P. fragile (n  6) and SIV-P. fragile-
coinfected animals (n  5) over various time periods were assessed by the
Wilcoxon rank-sum test statistic. Significance of the statistic was assessed by
permutation methods, i.e., by considering all possible ways 5 of the 11 animals
could have randomly been assigned to be coinfected. A similar analysis was
applied to determine differences between P. fragile and SIV-P. fragile-coinfected
animals in (i) percent infectivity, defined as the proportion of mosquitoes in-
fected, and (ii) the number of oocysts per infected mosquito. A mosquito was
considered infected if the midgut contained at least one oocyst.
For all analyses, one-sided P values were computed because of the lack of
power with such small sample sizes and the a priori hypotheses that change in
viral load, gametocytemia, and infectivity would be greater in coinfected animals.
All statistical analyses were carried out using SAS v9.2 (SAS Institute, Cary, NC),
StatXact 8 (Cytel Inc., Cambridge, MA), and R (www.R-project.org).
RESULTS
Development of a SIV-P. fragile coinfection model. We
sought to develop a SIV-malaria coinfection model in the
rhesus macaque because SIV infection in rhesus macaques is
an accepted model of HIV pathogenesis. Among the simian
parasites that generate P. falciparum-like infections, P. fragile
was chosen for the development of a coinfection model be-
cause the clinical symptoms resemble P. falciparum infection in
humans, it can be manipulated to develop as a chronic infec-
tion, it can be cultured in vitro, it has been previously used for
drug studies, and it is noninfectious to humans (11, 13, 16).
Based on previous reports (16, 21), rhesus macaques were
infected intravenously with P. fragile-infected erythrocytes. Pe-
ripheral parasitemia was determined by thin blood smear anal-
ysis (Fig. 1). Primary parasitemia developed within 14 days
postinoculation of P. fragile (DPI-P. fragile) and was associated
with a decrease in hematocrit and a transient fever (Fig. 1A).
In one animal, 33959, P. fragile-infected red blood cells could
not be detected during the first 2 weeks, and the animal there-
fore received a second inoculation with P. fragile-infected
erythrocytes on day 14 after the first P. fragile infection. Para-
sitemia unexpectedly rose to 6% within 3 days after the
second inoculation. As low parasitemia in P. falciparum-in-
fected humans can be missed by blood smear analysis (38), we
developed a quantitative PCR for the detection of P. fragile
DNA. Indeed, retroactive PCR analysis of the blood sample
obtained on day 11 after the first P. fragile inoculation con-
firmed that animal 33959 was positive by PCR for P. fragile
although no P. fragile-infected red blood cells could be de-
tected by blood smear analysis (see Fig. S1 in the supplemental
material). Higher sensitivity of P. fragile detection by PCR is
observed when data are presented as P. fragile copies per l of
blood, and highly congruent data of PCR and blood smear
analysis were obtained when P. fragile detection was reported
as infection of RBC (Fig. 1). Both methods were subsequently
applied to determine parasitemia. To establish a persistent P.
fragile infection, animals were treated with a subcurative dose
of 150 mg of quinine sulfate on two consecutive days when
parasitemia rose above 0.5% (Fig. 1A). This treatment re-
sulted in a stabilization of the hematocrit and low but persis-
FIG. 2. Pathological changes associated with coinfection. Shown are the spleen (A and B) and liver (C and D) from a representative SIV-P.
fragile-coinfected animal. (A) Several large closely apposed secondary lymphoid follicles with pale germinal centers were present in the red white
pulp of the spleen, while dark brown to black hemozoin was disseminated in the red pulp. (B) Magnification of the box from panel A, showing
granular hemozoin disseminated in the red pulp within a lymphocytic-histiocytic population. (C) Granular dark brown to black hemozoin was
disseminated in the Kupffer cells of the liver. (D) Magnification of the box from panel C.
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tent parasitemia reflected in periodic spikes in peripheral par-
asitemia (Fig. 1A).
In a first attempt to determine the effect of P. fragile infec-
tion on the virological outcome in SIV-infected macaques, we
infected animals with SIV 1 month prior to P. fragile infection.
The virological parameters of SIV infection in rhesus ma-
caques are well established, with peak viremia occurring within
the first 7 to 14 days postinoculation with SIV (DPI-SIV) and
the viral set point established between 28 and 56 DPI-SIV.
Based on our results from animals infected with P. fragile only,
we expected acute parasitemia to coincide with the establish-
ment of viral set point. Indeed, SIV-infected animals exhibited
peripheral parasitemia at approximately 14 DPI-P. fragile, at
which time quinine sulfate treatment was initiated. However,
despite an initial decline in parasitemia, the percentage of
infected erythrocytes rose to 50% within 2 weeks of treatment
(55 DPI-SIV), and the animals (n  2) were humanely eutha-
nized (Fig. 1B). This was direct evidence that coinfection al-
tered clinical outcome, but this outcome is not reflective of the
majority of coinfections that occur in humans. By extending the
quinine sulfate treatment from 2 days to 4 days, we were able
to effectively reduce parasitemia, stabilize the hematocrit, and
establish chronic SIV-P. fragile coinfection (Fig. 1C).
At necropsy, pathological findings were similar between
coinfected and P. fragile-only-infected animals. Gross findings
were dominated by a marked diffuse splenomegaly. Histolog-
ically, there was mild to marked lymphofollicular hyperplasia
in the spleen and in sampled lymph nodes (Fig. 2A). In addi-
tion, dark brown to black granular hemozoin was present
throughout the red pulp in the spleen and in the Kupffer cell
cytoplasm in the liver (Fig. 2). The liver also occasionally
exhibited extramedullary hematopoiesis, represented by in-
creased sinusoidal cellularity. Histological analysis of brain
sections did not reveal any lesions or evidence of P. fragile
cytoadherence (data not shown). However, animals were fol-
lowed only for 3 months, and quinine sulfate treatment may
have been sufficiently effective in preventing cerebral malaria.
Acute malaria transiently increased viremia in coinfected
animals. Consistent with previous results (35), the SIV-in-
fected macaques developed peak viremia within the first 7 to
14 DPI-SIV and reached the viral set point by week 6 postin-
oculation (Fig. 3A). In contrast, in SIV-P. fragile-coinfected
macaques, a transient 1- to 2-log increase in plasma viral RNA
copies was observed once acute parasitemia developed (Fig.
3A and B). Importantly, there was a statistically significant
difference (P  0.001) in the slope of plasma viral RNA be-
tween 42 and 56 DPI-SIV between SIV-only and SIV-P. fragile-
coinfected macaques.
We hypothesized that the increase in viremia might be
associated with immune activation induced by P. fragile in-
fection. In fact, primary parasitemia resulted in a marked
increase of activated CD4 T cells as measured by expres-
sion of Ki67 and CCR5 (Fig. 4A; see also Fig. S2A in the
supplemental material). Importantly, there was a temporal
overlap between the increase of CCR5 CD4 T cells, po-
tential target cells of SIV, during the acute phase of P.
fragile infection and the increase in viremia in SIV-P. fragile-
coinfected animals (Fig. 4A). In addition, concurrent with
FIG. 3. Transient increases in viremia during acute malaria. (A) Longitudinal SIV RNA levels in SIV-infected animals. Concurrent and
historical SIV-infected animals are represented by black open symbols and by the gray x, respectively. (B) Temporal correlation of viral RNA (blue)
and blood smear parasitemia (red) for SIV-P. fragile-coinfected animals. Note the increase in the viral RNA slope between days 42 and 56 PI-SIV
(black arrows).
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the rise of parasitemia, plasma NO levels were elevated
(Fig. 4B; see also Fig. S2B). Similarly, we noted an increase
in plasma levels of the proinflammatory cytokines IL-6 and
IFN-. This systemic immune activation induced by P. fragile
infection coincided temporally with increased frequencies of
activated CD4 T cells and increased viremia in SIV-P.
fragile-coinfected animals (Fig. 4; see Fig. S2).
Coinfection enhances the transmission risk of malaria.
There were no obvious differences in peripheral parasitemia
between P. fragile-only and coinfected animals. Importantly
though, only gametocytes, the sexual stages that are infective to
mosquitoes, are important in malaria transmission. The factors
triggering gametocyte development are unclear, but young
erythrocytes and reticulocytes have been implicated in game-
tocyte development both experimentally and in field studies
(33, 41, 42). Indeed, in both the P. fragile-infected and SIV-P.
fragile-coinfected animals, we observed an increase in the per-
centage of gametocytes, both absolute and relative to total
parasite number, during the initial drop in hematocrit (see Fig.
S3 in the supplemental material). The increase in gameto-
cytemia was confirmed by molecular analysis. The molecular
quantitation of gametocytes was based on the fact that the
switch from the asexual to the sexual stage of the parasite is
associated with the expression of distinct genes. However, the
sexual stage-specific genes for P. fragile have not been described.
P. fragile (despite causing clinical symptoms similar to P. falcipa-
rum in humans) is genetically closely related to P. vivax. Based on
known sexual stage-specific genes for P. vivax, we were able to
clone a P. fragile-specific sequence and developed a real-time
PCR method to complement the microscopic analysis for game-
tocytemia (see Fig. S1 in the supplemental material).
There was higher gametocytemia on days 14 to 27 after P.
fragile infection (42 to 55 DPI-SIV) in SIV-P. fragile-coinfected
animals relative to animals infected with P. fragile only (P 
0.05) (Fig. 5C, left panel). Because mosquitoes can become
infected following feeding on blood that lacks microscopically
detectable sexual-stage parasites and because detectable gameto-
cytemia does not always equate with mosquito infectivity (18), we
directly tested whether infectivity differed between P. fragile-in-
fected and SIV-P. fragile-coinfected animals through ex vivo mos-
quito feeding on peripheral blood. The proportion of mosquitoes
infected (i.e., with at least one oocyst in the midgut) was compa-
rable between P. fragile-only and coinfected animals, except at 42
to 55 DPI-P. fragile, when coinfected animals had a higher per-
centage of infectivity (P  0.07) (Fig. 5C, middle panel). Infected
mosquitoes feeding on blood from the SIV-P. fragile group had
more oocysts per midgut at 0 to 13, 14 to 27, and 28 to 41 DPI-P.
fragile (P  0.10) (Fig. 5C, right panel). As malaria is a vector-
borne disease, the measurement of oocysts in mosquito midguts is
a valid surrogate to assess transmission risk.
DISCUSSION
We developed a novel rhesus macaque model of SIV-P.
fragile coinfection to study HIV-1-P. falciparum coinfection
in humans. Our data demonstrate a transient increase of
SIV replication during the acute P. fragile infection period in
coinfected animals relative to animals infected with a single
pathogen. The rise in viremia was associated with elevated
cellular and systemic immune activation that may drive viral
replication (Fig. 6). Furthermore, oocyst development was
enhanced in mosquitoes that fed on blood from SIV-P.
fragile-coinfected animals compared to blood from P. fragile-
only-infected animals. These phenomena suggest that coin-
FIG. 4. Immune activation upon P. fragile infection in coinfected animals. (A) Percentage of Ki67 (dashed black line) or CCR5 (solid black)
cells in the CD3 CD4 T cell population in relation to viremia (blue line) and/or parasitemia (red line) over time in representative SIV-only-
infected, P. fragile-only-infected, and SIV-P. fragile-coinfected animals. (B) NO (solid black line), IFN- (dotted black line), and IL-6 (dashed black
line) levels in relation to viremia and/or parasitemia as described above. Lines below the x axis indicate concurrent rises in parasitemia and
activation markers.
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fection results in a higher risk of transmission of both HIV-1
and malaria.
Our model is most consistent with HIV-malaria coinfections
in areas of unstable malaria, where malaria is more severe due
to lack of preexisting immunity. Similarly, it would apply to
infants infected with HIV by mother-to-child transmission
prior to malaria infection. We acknowledge that the majority
of HIV-malaria coinfections in humans are likely due to re-
FIG. 5. Gametocytemia and mosquito infectivity. (A) Blood smears of P. fragile-infected erythrocytes with ring-stage parasites (left) and
increased gametocytes in a representative SIV-P. fragile-coinfected animal (right). (B) Examples of the relationship between blood smear
gametocytemia (red line), mosquito infectivity (gray line), and oocyst frequencies in mosquitoes (black line) over time in representative P.
fragile-infected and SIV-P. fragile-coinfected animals, respectively. (C) Box plots of gametocytemia (left), percent infectivity (middle), and oocysts
per infected mosquito (right) between P. fragile and SIV-P. fragile-coinfected animals. **, P  0.05; *, 0.05 	 P  0.10.
FIG. 6. Temporal relationship between immune, virological, and parasitological parameters in SIV-P. fragile-coinfected animals. SIV-infected
macaques subsequently infected with P. fragile exhibited acute parasitemia and concurrent systemic immune activation. This activation could drive
viral replication and provide more target cells for SIV, thereby elevating viremia. Coinfected macaques also exhibited increased malarial
transmission compared to P. fragile-only-infected macaques during this acute infection period.
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peated malaria infection beginning in early childhood, fol-
lowed by HIV infection during adolescence. The SIV-P. fragile
coinfection model described here is a novel model and as such
was developed based on a wealth of data on the well-accepted
SIV infection model of HIV infection in humans. Having suc-
cessfully established this model, it can now be expanded to test
the various scenarios of HIV-P. falciparum coinfection in hu-
mans.
During the initial rise in peripheral parasitemia of acute
malaria infection, we observed a transient increase in viremia
in coinfected animals, a trend which has been observed in
human coinfections (5, 24, 28). Even an only slightly and/or
transiently increased risk of HIV could have tremendous con-
sequences in areas of high disease incidence. Thus, under-
standing of the underlying mechanisms that promote more
severe pathogenesis and potential higher transmission rates is
essential. We present evidence that immune activation, as as-
sessed by increased frequencies of Ki67 and CCR5 CD4 T
cells, and also by elevated systemic levels of NO and proin-
flammatory cytokines, is induced by P. fragile and is associated
with a transient increase in viremia. We hypothesize that in-
creased numbers of CCR5 CD4 T cells translate into higher
numbers of target cells for the virus and that NO, through the
activation of NF-
B, can directly induce HIV replication in
virally infected cells (6, 39, 40, 51). In addition to affecting
immune activation at this acute time point, we postulate that
coinfected animals may experience heightened activation in
the longer term that could promote earlier immune exhaustion
and onset to simian AIDS. During the relatively short period of
coinfection in the current study, pathological differences could
not be detected between tissues of single and coinfected ani-
mals. Long-term studies of the coinfection model are war-
ranted to follow the combined effect of malaria and SIV upon
the immune system and clinical outcome.
With regard to the effect of coinfection on malaria patho-
genesis, the 2-day quinine sulfate treatment that was effective
in establishing chronic malaria infection in P. fragile-only-in-
fected animals was not sufficient to control acute parasitemia
in acutely SIV-infected animals. SIV and HIV are known to
affect many players in the immune system, and we hypothesize
that SIV-induced immunosuppression resulted in the different
treatment outcomes. SIV infects CD4 T cells, resulting in cell
death, and leads to CD8 T cell exhaustion (36). Loss of T
helper function will impair multiple aspects of the host im-
mune response. We observed that the chronically coinfected
animals produced a less robust, although not significant, anti-
malarial humoral response than the chronically infected P.
fragile animals (see Fig. S4 in the supplemental material). Sim-
ilar findings of impairment of humoral immunity against ma-
larial parasites were reported in the SIV-P. cynomolgi study
and in pregnant coinfected women, suggesting SIV/HIV plays
a role in diminishing the antibody response (26, 32). However,
at this early time after SIV infection, impaired innate factors
likely contributed to the lack of control of parasitemia. It is
well known that dendritic cell frequencies and function are
already reduced in acute HIV and SIV infection (7, 17). Sim-
ilarly, Plasmodium spp. are known to directly alter dendritic
cell function (31, 45). Coinfection with SIV and P. fragile may
compound the immunologic damage induced by each patho-
gen, leading to more severe morbidity and pathology in coin-
fected individuals.
A key finding of our study was that coinfected animals ex-
hibited higher gametocytemia during acute P. fragile infection
than animals infected with P. fragile only. Importantly, during
that same time period, oocyst development was significantly
higher in mosquitoes that fed on blood obtained from SIV-P.
fragile-coinfected animals than mosquitos that fed on blood
from P. fragile-only-infected animals. These data indicate a
heightened transmission risk of malaria during acute para-
sitemia in coinfected individuals. Unlike our model of chronic
malaria that was induced by subcurative quinine sulfate treat-
ment to develop the SIV-P. fragile coinfection model, humans
in areas of endemicity are continuously and repeatedly chal-
lenged with new infections. Therefore, we hypothesize that the
elevated infectivity to mosquitoes we observed during acute
infection could occur during every new infection in humans.
This would significantly increase the overall effect of coinfec-
tion on transmission, a hypothesis that could be tested in the
primate model via repeated inoculations of P. fragile after
curing the initial parasite infection with a higher treatment
dose (16).
It was beyond the scope of the current study to establish a
causative relationship, but the temporal patterns observed
(Fig. 6) clearly suggest that immune activation during the acute
parasitemia period in SIV-infected macaques was associated
with the transient increase in viremia and enhanced mosquito
infectivity. Thus, the data indicate that the transmission risks of
both SIV/HIV and malaria are increased in coinfected individ-
uals, at least during certain phases of coinfection.
The current study describes the development and key clini-
cal and immunologic features of SIV-P. fragile coinfection.
Future studies with larger numbers of animals and various
temporal patterns of coinfection are required to further de-
velop our understanding of HIV-malaria coinfection in hu-
mans. This model will likely provide a useful tool in defining
the underlying immune mechanisms leading to disease exacer-
bation in coinfected individuals and in the design of novel
therapeutics and vaccines to combat HIV-malaria coinfection
in humans.
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